Abstract. Decreased activity ofthe guanine nucleotide regulatory protein (N) of the adenylate cyclase system is present in cell membranes ofsome patients with pseudohypoparathyrodism (PHP-Ia) whereas others have normal activity of N (PHP-Ib). Low N activity in PHPIa results in a decrease in hormone (H)-stimulatable adenylate cyclase in various tissues, which might be due to decreased ability to form an agonist-specific high affinity complex composed of H, receptor (R), and N. To test this hypothesis, we compared f3-adrenergic agonist-specific binding properties in erythrocyte membranes from five patients with PHP-Ia (N = 45% of control), five patients with PHP-Ib (N = 97%), and five control subjects. Competition curves that were generated by increasing concentrations ofthe (3-agonist isoproterenol competing with ['251]pindolol were shallow (slope factors < 1) and were computer fit to a two-state model with corresponding high and low affinity for the agonist. The agonist competition curves from the PHP-Ia patients were shifted significantly (P < 0.02) to the right as a result of a significant (P < 0.01) decrease in the percent of fl-adrenergic receptors in the high affinity state from 64±22% in PHPIb and 56±5% in controls to 10±8% in PHP-Ia. The agonist competition curves were computer fit to a "ternary These in vitro findings in erythrocytes taken together with the recent observations that in vivo isoproterenolstimulated adenylate cyclase activity is decreased in patients with PHP (Carlson, H. E., and A. S. Brickman, 1983 , J. Clin. Endocrinol. Metab. 56:1323-1326 are consistent with the notion that N is a bifunctional protein interacting with both R and the adenylate cyclase. It may be that in patients with PHP-Ia a single molecular and genetic defect accounts for both decreased HRN formation and decreased adenylate cyclase activity, whereas in PHP-Ib the biochemical lesion(s) appear not to affect HRN complex formation.
this hypothesis, we compared f3-adrenergic agonist-specific binding properties in erythrocyte membranes from five patients with PHP-Ia (N = 45% of control), five patients with PHP-Ib (N = 97%), and five control subjects. Competition curves that were generated by increasing concentrations ofthe (3-agonist isoproterenol competing with ['251 ]pindolol were shallow (slope factors < 1) and were computer fit to a two-state model with corresponding high and low affinity for the agonist. The agonist competition curves from the PHP-Ia patients were shifted significantly (P < 0.02) to the right as a result of a significant (P < 0.01) decrease in the percent of fl-adrenergic receptors in the high affinity state from 64±22% in PHPIb and 56±5% in controls to 10±8% in PHP-Ia. The agonist competition curves were computer fit to a "ternary Receivedfor publication 28 October 1983 and in revisedform 9 January 1984. complex" model for the two-step reaction: H + R + N = HR + N = HRN. The modeling was consistent with a 60% decrease in the functional concentration of N, and was in good agreement with the biochemically determined decrease in erythrocyte N protein activity.
These in vitro findings in erythrocytes taken together with the recent observations that in vivo isoproterenolstimulated adenylate cyclase activity is decreased in patients with PHP (Carlson, H. E., and A. S. Brickman, Introduction Pseudohypoparathyroidism (PHP)' is a rare genetic disorder characterized by end organ resistance to the effects ofparathyroid hormone. Albright and colleagues (1) initially reported this disease and recognized that a particular phenotype, marked by short stature with shortening of the metacarpals and/or metatarsals, may accompany the biochemical disorder in PHP (1) .
Recently, several investigators have recognized that end organ resistance to a variety of hormones may occur as part of the PHP disorder. Thus, dysfunction of thyroid (2) (3) (4) , gonadotropin (5), prolactin (6) (7) (8) , and glucagon (4) action have been described as a consequence ofhormone resistance. Very recently, a blunted plasma cyclic adenosine monophosphate (cAMP) response to the infusion of the f3-adrenergic agonist isoproterenol has been described in patients with PHP (9) . Numerous investigations have been directed at determining whether a ubiquitous biochemical defect underlies the end organ resistance to PHP. These investigations have focused on the hormone (H) receptor-adenylate cyclase complex since it was first found that patients with PHP do not have a significant rise in urinary cyclic AMP excretion after the administration of PTH (10) .
The adenylate cyclase-receptor complex consists of at least three separable plasma membrane components: the hormone receptor (R), the catalytic unit (C) of adenylate cyclase, and a guanine nucleotide regulatory protein (G/F or N protein) which serves to couple the receptor to the catalytic moiety (1 1) . Several lines of evidence have suggested decreased activity of this N protein in activating adenylate cyclase in various tissues (including circulating cells) of some patients with PHP (PHP-Ia) most of whom had Albright's hereditary osteodystrophy (12) (13) (14) (15) (16) (17) . By contrast, phenotypically normal patients, who demonstrate abnormal urinary cAMP excretion in response to parathyroid (PTH) infusion, have normal assayable N protein activity in circulating cells (PHP-Ib).
The f3-adrenergic receptor-N protein-adenylate cyclase complex is the most extensively studied and best understood hormonal-adenylate cyclase system (18) (19) (20) . Previous work has demonstrated that hormonal agonists promote the coupling of (-adrenergic receptors with the N protein to form a high affinity complex (HRN), which is an intermediate in the pathway to adenylate cyclase activation (21) . Guanine nucleotides, which are required for the hormonal activation of adenylate cyclase, revert the high affinity state of the receptor to its low affinity form (HR), concurrent with activation of the adenylate cyclase enzyme. Quantitation of the percentage of receptors in the high and low affinity complexes can be accomplished by computer modeling of agonist competition curves with f3-adrenergic antagonist radioligands (18) (19) . Cells that either lack the N protein on a genetic basis (cyc-) (22) or in which there is impaired RN coupling for any reason show absent or impaired formation of this high affinity agonist-receptor complex. As a result, such competition curves are shifted to the right (to higher concentration of isoproterenol inhibiting 50% of radioligand binding [EC50]).
Accordingly, we assessed the ability of(3-adrenergic receptors of human erythrocytes to form high affinity receptor complexes in erythrocyte membranes that were derived from five control subjects, five patients with PHP-Ia (low erythrocyte N protein), and five patients with PHP-Ib (normal erythrocyte N protein). This procedure required improvement of methods for detecting the small number of f3-adrenergic receptors in these cells (23) .
The results shed further light both on the nature of the hormoneresponsive adenylate cyclase system and on the pathophysiologic defects in patients with pseudohypoparathyroidism.
Methods
We studied five patients with pseudohypoparathyroidism type-Ia, five patients with pseudohypoparathyroidism type-Ib, and five healthy volunteers.
The clinical and laboratory diagnosis of PHP and assessment of the presence or absence of Albright's hereditary osteodystrophy was made by Dr. Drezner except for patient A.M. who was evaluated by Dr. Spiegel (see Table I ). The diagnosis of PHP was further confirmed in the patients by measurement of the urinary cAMP response to PTH infusion (10) , which in all cases was <20 ,gmol cAMP/g creatinine in the urine. In addition, all patients demonstrated a reduced phosphaturic response to PTH and elevated tubular maximum for reabsorption of phosphate. Each patient was initially evaluated while he was untreated and hypocalcemic. The present studies were performed after long-term treatment with vitamin D and/or calcium supplementation in each patient and with maintenance of normocalcemia.
At the time of the study, PTH hormone levels were determined by three different radioimmunoassays, which have been previously described and validated (24) (25) (26) . "PTH assay 1" is a carboxy-terminal PTH assay performed at the Mayo Clinic (24) . "PTH assay 2" is performed at Duke University and is also a carboxy-terminal PTH assay (25) . "PTH assay 3" was performed on one patient (A.M.) and is a mid-region (amino acids 44-68) assay (26) .
Human erythrocyte membrane preparation. After obtaining informed consent, we obtained 200 ml of whole blood via venipuncture. A 45-ml aliquot of this whole blood was collected into 5 ml of acid-citratedextrose anticoagulant and immediately placed on ice but not frozen. Erythrocyte membranes were prepared within 24 h of venipuncture for determination of N protein activity (13) . N protein was assayed according to the reconstitution assay described by Kaslow et al. (27) but was modified by incubating the erythrocyte membrane extracts and cycmembranes for 20 min at 30'C in the presence of adenylate cyclase assay mixture before the addition of [32P]ATP and the performance of the assay. We anticoagulated the remaining 155 ml of whole blood by using U. S. Pharmacopoeia sodium beef lung heparin (The Upjohn Co., Kalamazoo, MI) (1,000 U ofheparin per 49 ml ofwhole blood) and prepared erythrocyte ,B-adrenergic receptor-containing membranes. The erythrocytes were sedimented by the addition of 10 ml of 3% Dextran (Dextran T-500, Pharmacia Fine Chemicals, Piscataway, NJ) in normal saline to 25 ml of whole blood and left undisturbed for 20 min. The supernatant layer, which contained the plasma and most ofthe leukocytes and platelets, was discarded and 50 ml of erythrocytes was used for subsequent steps. These erythrocytes were washed three times with normal saline by centrifugation at 1,600 g and both the supernatant and small buffy coat layer on top of the erythrocyte layer were aspirated and discarded. We used 25 ml of the total volume of washed erythrocytes for the erythrocyte ,B-adrenergic receptor assays.
I ml ofthe washed erythrocyte preparation was used for determination of the erythrocyte count and to assess the homogeneity of the that the observed binding was associated with membranes derived from other cell types. We found a low level of leukocyte and platelet contamination in the erythrocyte layer before lysis of cells for membrane preparation. An average of250±130 leukocytes and 5,500±3,000 platelets per cubic millimeter were present in control preparations; 100±50 leukocytes and 5,500±2,900 platelets, in PHP-Ia patients; and 100±170 leukocytes and 5,200±3,200 platelets, in PHP-Ib preparations. Thus, the level of leukocytes and platelets present in the erythrocyte preparation was consistently <5% ofthe level found in the whole blood ofthe donor. 25 ml of washed erythrocytes was lysed by the addition of 225 ml of ice-cold distilled water and allowed to sit undisturbed for 10 min on ice. Subsequently, the lysed erythrocytes were gently homogenized on ice in a 40-ml Dounce homogenizer. An equal volume of cold membrane buffer (75 mM Tris-HCI buffer, pH 7.5, containing 25 mM MgCl2 and 1.5 mM EDTA) was added to the homogenate and centrifuged at 40,000 g for 10 min at 40C. The hemoglobin-containing supernatant was discarded and the membrane pellet was then washed three times with membrane buffer by centrifugation at 40,000 g for 10 min at 4VC. The resulting white or light pink pellet was then resuspended to a volume of 50 ml with membrane buffer and used for the f3-adrenergic receptor assay. This membrane preparation was also assayed for protein concentration according to the method of Lowry et al. (28) .
Human erythrocyte membrane 0-adrenergic receptor assay. We performed competition and saturation binding isotherms on membranes from all subjects by using standard radioligand binding techniques (29) .
['251I]Iodopindolol was prepared from (-)pindolol by radioiodination with chloramine T and ['251I]NaI (30) . The product was completely resolved from uniodinated pindolol and was therefore assumed to have theoretical specific activity of 2,200 Ci/mmol.
Saturation binding isotherms were constructed using 0. [125I]pindolol by filtering the membranes over Whatman GF/C glass fiber filters and then washing with 25 ml of cold membrane buffer. The filters were then counted in an Auto Gamma 800 gamma counter (Packard Instrument Co., Inc., Downers Grove, IL). Competition binding isotherms were constructed by using isoproterenol concentrations in the assay from 10-9 to 10-3 M in competition with 200 pM ['25I]pindolol for binding to erythrocyte membrane f3-adrenergic receptors. The incubation and washing conditions were as described for the saturation binding isotherms and the total volume of the assay was also 0.6 ml (100 Ml of isoproterenol or buffer, 100 ul of ['251I]pindolol and 400 Ml of membranes) and were performed in duplicate.
Competition binding isotherms were performed in parallel in the presence and absence of l0-4 M guanylyl-imidodiphosphate (Gpp(NH)p) (Boehringer-Mannheim Biochemicals, Indianapolis, IN).
We attempted to measure adenylate cyclase in these human erythrocyte membranes according to the method of Salomon et al. (31) . Despite the addition of theophylline, forskolin, and the use of various incubation conditions and temperatures, no fluoride-or isoproterenolstimulatable adenylate cyclase could be measured.
Data analysis. Data from the saturation and competition binding assays were analyzed and modeled by computer techniques as previously described (18, 19, 32) . Competition curves were fit with a four-parameter logistic equation, which provided the slope factor and EC50 for each curve (32) . Next, the curves were modeled according to the law of mass action to provide the best fit to a model, assuming a single state of the receptor or to a model assuming two states (high and low affinity) of the receptor. A two-affinity state model was accepted only ifit was shown to significantly (P < 0.05) improve the fit over a single-affinity state model. This program provided the affinity constants and proportions of the receptors in the high affinity or low affinity state for isoproterenol (9) . This program was also used to fit the saturation binding isotherms for [125I] pindolol and invariably such data were adequately modeled to a one-site fit.
When modeling the competition curves according to the law of mass action, the following approach was taken. The data from each subject were first modeled individually and was then averaged with data from other subjects in three different ways. The first method was to plot every data point from each of the five people in each donor group (normal controls, PHP-Ia, PHP-Ib) and then have the computer fit the best curve to all the data points for each group of patients. The second method was to average the binding data from each group of patients at a given concentration of competing isoproterenol and to generate a single competition binding isotherm from the patient data within a donor group. The third technique was to average the parameter values obtained from each patient's data individually within each of the three donor groups. These three methods of averaging the data within a group of donors yielded results that were virtually identical. The data and curves obtained by the second method above are presented in this paper.
As a final approach, the isoproterenol competition curves from the three subject groups were analyzed by using the "ternary complex" model, which we have previously proposed and validated to account Fig. 2 ). (c) The radioligand had no effect on the equilibrium between the free and coupled forms of the receptor so that it had identical affinity for R (18, 19) . Although the parameter L might have varied between the groups, it was set constant since (a) excellent fits to the data could be obtained when L values were shared among the three groups and (b) the major hypothesis that we wished to test with the ternary complex modeling was whether the binding data were consistent with the biochemically established decrease in the concentration of N in the membranes.
Statistical comparisons. With each of the three types of curve-fitting programs used, parameter values derived from the different patient groups were compared by constraining the computer fit competition curves from the different groups to share common values (e.g., EC~, slope factor, Kd, etc.) and testing for worsening of the fit while keeping other values constant. Parameters werejudged as significantly different ifsharing of these parameters led to a significant (P < 0.05) worsening of the fit compared with that obtained when parameters were determined independently for each group (19) . In other cases, parameters from the differing groups were compared by a one-way analysis of variance.
Results
Characteristics ofligand binding to the human erythrocyte membrane beta-adrenergic receptor. As shown in Fig. 1 (Fig. 2 A-C 10.2±8.4t
<0.001
* All values are not significantly different from control (P > 0.05). * In this case a two-site fit was not significantly better than a one-site fit since so little of the high affinity state of the receptor was formed. However, for purposes of comparison this value was used rather than a value of 0% (the value implied by a one site fit).
All of these lines of evidence indicate that platelet or leukocyte binding did not account for the observed binding in these preparations but rather that a low level of receptors is, in fact, present on erythrocytes.
Comparison of isoproterenol competition curves between control subjects and PHP patients. Isoproterenol competition curves in the presence or absence of Gpp(NH)P, representing the averaged, normalized data for each of five control, PHP-Ia and PHP-Ib subjects, are shown in Fig. 4 and the various parameters derived from these curves are summarized in Table  II . The competition curves for control subjects and patients with PHP-Ib are virtually identical. The average EC50 for controls was 4.7 X 10-7 M while that for patients with PHP-Ib was 4.9 X l0-7 M without Gpp(NH)p (P = NS). In the presence of Gpp(NH)p these values were 2.0 X 10-6 M and 1.9 X 10-6 M for controls and PHP-Ib patients, respectively (P = NS). In the absence ofGpp(NH)p the slope factor ofthe isoproterenol competition curve derived from subjects with PHP-Ib is not significantly steeper than for control subjects (P = 0.48); however both competition curves were steep with slope factors that approximated 1.0 in the presence of Gpp(NH)p. Similarly, both the PHP-Ib and control subjects have -60% of their #2-adrenergic receptor population in the high affinity form in the absence of Gpp(NH)p. The percentage of receptors in the high affinity state was 64% for the PHP-Ib patients and 56% for controls but this difference was not statistically different (P > 0.5). In contrast, visual inspection ofthe curves in Fig. 4 illustrates that the competition curve representing data from patients with PHP-Ia is different from that ofsubjects with PHP-Ib or controls in the absence of Gpp(NH)p. The curve for the PHP-Ia group is shifted to the right with an EC50 of 1.2±0.2 X 10-6 M, which is significantly different than the curve for the PHP-Ib or control groups (P < 0.001).
The rightward shift and steepness ofthis curve are compatible with decreased formation of the high affinity receptor complex (19) , which is presumably a reflection of decreased formation of HRN (18, 19) . As shown in Table II , only 10% ofthe receptors are found to be in the high affinity form by computer modeling.
Thus, a significantly lower percentage of the 032-adrenergic receptors are able to form a high affinity complex in the erythrocytes of PHP-Ia patients than in the controls (P < 0.01) or the PHP-Ib patients (P < 0.01). Importantly, the dissociation constants for the isoproterenol competition curves in the absence of Gpp(NH)p were not statistically different between control and PHP-Ib and PHP-Ia patients.
To assess if a change in the stoichiometric ratio of N/R could explain the alterations in isoproterenol competition curves documented in Fig. 4 and (18) . This modeling suggested a -60% reduction in the functional N pool in the PHP-Ia patients. Although the results of the computer modeling do not categorically exclude a reduction in the L value for HRN complex formation, the calculated reduction in N protein concentration is consistent with the reduction in N protein activity observed in the biochemical assays of N.
In other situations where N is genetically deficient, such as the cyc-variant of S49 lymphoma cells (22) , or in situations where there is uncoupling of R from N such as desensitization (35) , hypothyroidism (36) , or hypoadrenalism (37) , there is a reduction in the agonist-specific high affinity binding component that is demonstrated by a right-shifted and steepened agonist competition curve. This was precisely the situation documented in this study for the competition curves of the PHP-Ia patients. It is reasonably well established that formation of the HRN complex is a necessary prerequisite for cAMP formation (20) . Thus, assuming that the results in erythrocytes are relevant to the situation in other tissues, it is possible that the decreased ability to form the HRN complex contributes to the decreased PTH, thyroid-stimulating hormone and other N protein-me- However, the results of our work demonstrate that in vitro, agonist-induced receptor-N protein coupling is normal in erythrocytes from PHP-lb patients. Thus, it is likely that a molecular understanding of the decreased cAMP formation in PHP-Ib patients will have to await development of further techniques for the investigation of this problem. A major hypothesis that has been tested by the present work is whether the defect in the functional pool of N molecules present in the cell membranes of patients with PHP-Ia would be discerned in the patterns of agonist binding to 13-adrenergic receptors. As noted, this hypothesis was confirmed by our observations. These data are consistent with the notion that in PHP-Ia patients a quantitative defect in a single gene product (i.e., N or some component thereof) might be responsible both for the ligand binding abnormalities demonstrated in this work and for decreased adenylate cyclase activation demonstrated in other work (12, 17) . Our findings further support the idea of a single bifunctional N protein that interacts with both R and C.
